Cape to Cape for Cannabis nears as organisers urge final registrations by Adam Sheldon March 19, 2026June 8, 2026 With just four weeks to go until this year’s Cape to Cape for Cannabis event in […]
The People’s Plant pushes toward $1.5m as CSF offer nears close by Adam Sheldon March 19, 2026March 19, 2026
Lancet clinical review paper: why absence of evidence is not evidence of absence by Andrew Proudfoot March 18, 2026March 18, 2026
Meet the appointed members of the scheduling committee who could shape THC’s regulatory future by Adam Sheldon and Steve Jones March 18, 2026March 19, 2026
Cash shortage offers only ‘limited window’ to sell Helius, administrator tells creditors by Steve Jones March 18, 2026March 18, 2026
Australian exports to Germany triple as imports top 200 tonnes by Adam Sheldon March 18, 2026March 18, 2026
High THC ‘doesn’t mean a better therapeutic effect’, genetic expert tells prescribers by Adam Sheldon March 17, 2026March 18, 2026
News in brief: Vitura signs MedReleaf deal; Neurotech initiates first site for Phase 3 autism trial by Adam Sheldon March 17, 2026June 8, 2026
‘Lawful practice’ not enough to avoid regulatory action, warns former AHPRA advisor by Adam Sheldon March 17, 2026March 17, 2026
Former Cannim research lead takes senior role at Medigrowth by Steve Jones March 16, 2026March 19, 2026
